

## **Helix BioMedix Peptide Studied in Acne Patients**

*Sep 08, 2003 - Bothell, Washington*

Helix BioMedix announced today the completion of a preliminary study designed to evaluate the efficacy of one of the Company's proprietary peptides, HB64, in reducing the severity of mild to moderate acne symptoms.

Pennsylvania-based DermDx Centers for Dermatology conducted the 12-week study on 20 subjects with mild to moderate acne. They ranged in age from 14 to 36. The participants applied a gel solution containing 0.1% of the peptide to affected areas of their faces twice a day. Both physician examinations and self-assessment questionnaires were used in assessing the results.

Seventy-five percent of the participants showed clinical improvement as assessed by physicians. Eighty-five percent of the participants reported the peptide gel helped their complexion, and ninety percent indicated that the peptide gel was equal or better than other acne products they had used previously. None of the participants reported irritation or sensitization and none dropped out of the study due to product-related issues.

Four out of five persons will suffer from acne sometime between the ages of 11 and 30, according to Dr. Stephen M. Schleicher, Director of DermDx Centers for Dermatology.

Helix BioMedix plans to license its proprietary peptides to other firms, which would develop and take to market products using those peptides.

"The Company is actively engaged in discussions with a number of firms that have expressed interest in licensing a peptide-based anti-acne product," noted Helix BioMedix CEO Stephen Beatty.

Another of the Company's proprietary peptides, HB107, currently is being evaluated as a wound-healing agent. Results of early-stage testing are available on the Company's website, [www.helixbiomedix.com](http://www.helixbiomedix.com).

"Obviously, there is more testing to be done on both HB64 and HB107," said Beatty, "but I'm very optimistic and excited based on the results I have seen so far."

### **About Helix BioMedix:**

Helix BioMedix, Inc. is an early-stage biotechnology company whose mission is to become the industry leader in developing and commercializing bioactive peptides (small proteins). The antimicrobial and wound healing properties of these peptides qualify them for inclusion in a wide range of both pharmaceutical and consumer products. The Company is currently focused on the development of selected peptides as pharmaceutical agents for use in treating cystic fibrosis, sexually-transmitted diseases, and in wound healing. Non-pharmaceutical applications being pursued by Helix BioMedix include adjuvants for cosmetics/cosmeceuticals and wide-spectrum biocides. Located in Bothell, Washington, Helix BioMedix is a product development company organized to derive revenue from licensing its peptide-based technology to

partners with sales, marketing, and/or manufacturing expertise. More information about the Company and its proprietary peptides can be found on the Company's website at [www.helixbiomedix.com](http://www.helixbiomedix.com).

---

### **Important Notice:**

*Except for historical information presented in this press release, matters discussed herein may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on the opinions and estimates of management only as of the date of this release and are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Factors that might cause such a difference include, but are not limited to, uncertainties related to the Company's access to capital, the progress, costs and results of any clinical trials undertaken by the Company, progress of research and development projects, and uncertainties related to whether the Company's product candidates would ultimately achieve commercial success.*

*Reference should be made to Helix BioMedix's public disclosure documents including its Annual Report on Form 10-KSB, filed with the Securities and Exchange Commission for a more detailed description of such factors.*

*Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this press release. Helix BioMedix disclaims any intent or obligation to update these forward-looking statements to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.*

For more information please contact:

R. Stephen Beatty  
President and CEO

(425)402-8400

[sbeatty@helixbiomedix.com](mailto:sbeatty@helixbiomedix.com)